All Topics
All Topics
Technology
Technology
Design
Design
Programming
Programming
Science
Science
News
News
Gaming
Gaming
Entertainment
Entertainment
Business
Business
Finance
Finance
Sports
Sports
Health
Health
Food
Food
Travel
Travel
Art
Art
Music
Music
Books
Books
Education
Education
Politics
Politics
Personal
Personal
No algorithm. No AI slop. No ads. Just RSS. Pro-human. Indie writers. Real journalism. Open web. Chronological. Hand toasted.

Life Biosciences Doses First Patient in FDA-Approved Gene Therapy Trial for Age-Related Blindness

By

Matthew Phelan

15h ago· 4 min readenNews

Summary

Life Biosciences has dosed its first patient in an FDA-approved clinical trial testing a gene therapy designed to reverse cellular aging. The therapy targets glaucoma by aiming to regenerate aging neurons in the optic nerves, specifically retinal ganglion cells that typically die irreversibly in the condition. This marks a significant milestone in high-stakes human testing of anti-aging gene therapies.

Key quotes

· 3 pulled
Buckle up. High-stakes human testing has now begun on a gene therapy that promises to reverse aging at the cellular level.
Life Biosciences's modest goal is to regenerate aging neurons in the optic nerves of patients struggling with glaucoma—a condition that often includes the irreversible death of neurons known as retinal ganglion cells.
the Boston-based longevity startup announced on Tuesday that it's just dosed its first patient
Snippet from the RSS feed
Life Biosciences says it just dosed its first patient in an FDA-approved clinical trial to reverse age-related blindness.

You might also wanna read